CID-2858522 – 25 mg

Brand:
Cayman
CAS:
758679-97-9
Storage:
-20
UN-No:
De Minimis - 2811 / 6.1

CID-2858522 is an 2-amino benzimidazole that inhibits activation of the NF-κB pathway induced by the PKC activator PMA with an IC50 value of 0.07 μM.{24527} It has been shown to inhibit IL-8 production induced by PKC activators in HEK293 cells (IC50 ≤ 0.1 μM), attenuate CD3/CD28 and PMA/ionomycin-induced production of IL-2 by Jurkat T cells (IC50 ≤ 5 μM), and prevent anti-IgM-stimulated proliferation of mouse B-lymphocytes (IC50 = ∼2 μM).{24527} CID-2858522 does not, however, inhibit the NF-κB pathway activated by TNF-α.{24527}  

 

SKU: - Category:

Description

A selective inhibitor of PKC-induced NF-κB pathway activation (IC50 = 0.07 μM); inhibits IL-8 production in HEK293 cells (IC50 ≤ 0.1 μM), attenuates production of IL-2 by Jurkat T cells (IC50 ≤ 5 μM), and prevents proliferation of mouse B-lymphocytes (IC50 = ∼2 μM)


Formal name: 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-[2-[(3-hydroxypropyl)amino]-5,6-dimethyl-1H-benzimidazol-1-yl]-ethanone

Synonyms:  ML-029

Molecular weight: 465.6

CAS: 758679-97-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|TNF-α/NF-κB Signaling||Research Area|Cell Biology|Cell Signaling|NF-κB Signaling||Research Area|Epigenetics, Transcription, & Translation|Transcription Factors||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Autoimmunity||Research Area|Immunology & Inflammation|Innate Immunity|Pattern Recognition||Research Area|Immunology & Inflammation|Innate Immunity|STING||Research Area|Infectious Disease